Filing Flows › NovoCure (NVCR) › Q1 2026
NovoCure (NVCR) Q1 2026 earnings results (first quarter 2026)
10-Q filed Apr 30, 2026
NovoCure (NVCR) reported revenue of $174M for the first quarter 2026 (Q1 2026), +12% from a year earlier and -0.2% from the quarter before. Operating margin was -38.7%, net loss $71.1M (40.9% of revenue).
NovoCure, Q1 2026: revenue $174M (+12% year over year), operating margin -38.7%, net loss $71.1M, operating cash flow −$13.5M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $174M | -0.2% | +12% |
| Operating profit | −$67.4M | — | — |
| Net earnings | −$71.1M | — | — |
| Operating cash flow | −$13.5M | — | — |
What changed
Revenue was $174.1M in Q1 2026, up 12% year over year and roughly flat from the previous quarter.
Gross margin was 77.6%, up 2.5 points from Q1 2025. Operating costs exceeded revenue by $67.4M, an operating margin of -38.7%. Operating expenses grew 31% against revenue growth of 12%. The fastest-growing cost line was General & admin (+92%). The quarter ended with a net loss of $71.1M, wider than the previous quarter's $24.5M loss.
Operating cash flow was −$13.5M. Non-cash charges added back $4.1M of depreciation and amortization and $63.0M of share-based compensation. Working capital and other items used $9.5M. Capital expenditures of $5.2M exceeded it, leaving free cash flow of −$18.7M.
Questions
What was NovoCure's revenue in the first quarter 2026?
NovoCure (NVCR) reported revenue of $174M for the first quarter 2026 (Q1 2026), +12% from a year earlier and -0.2% from the quarter before.
Was NovoCure profitable in the first quarter 2026?
Operating loss was $67.4M (-38.7% of revenue) and net loss $71.1M.
Source: NovoCure 10-Q on SEC EDGAR.